ClinicalTrials.gg
Not yet recruitingNCT07908537Updated Nov 2, 2026

A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)

A Phase 3 interventional study of Gocatamig and Durvalumab in Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Updated Nov 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
564
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Small Cell Lung Carcinoma by Merck & Co., Inc — 3 open to participants now, 8 under way, 3 of them phase 3. Small Cell Lung Carcinoma · Merck & Co., Inc.

Planned enrollment
3rd of 12
564 · median 280
Started
2026
with 1 other
Phase 3
4 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Small Cell Lung Carcinoma by Merck & Co., Inc, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2026, is one of 4 in phase 3, and was the 12th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

3 of the 12 studies in Small Cell Lung Carcinoma by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Small Cell Lung Carcinoma by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers are looking for new ways to treat limited-stage small cell lung cancer (LS-SCLC). LS-SCLC is a type of lung cancer that has not spread from the lung to other parts of the body. Researchers want to learn if gocatamig given with durvalumab can treat LS-SCLC.

The main goal of this trial is to learn if participants who receive gocatamig with durvalumab live longer without the cancer getting worse than those who receive durvalumab alone.

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has or cytologically confirmed limited-stage small cell lung cancer (LS-SCLC) defined as Stage I-III by American Joint Committee on Cancer 9th Edition Cancer Staging
  • Has received appropriate definitive concurrent chemoradiotherapy (CRT; 4 cycles of platinum-based chemotherapy concurrent with radiotherapy) per protocol
  • Has achieved complete response, partial response, or stable disease and did not progress per protocol following definitive, platinum-based chemotherapy concurrent with radiotherapy
  • Is not expected to require tumor resection during the study
  • Is able to submit a of a tumor lesion not previously irradiated
  • Has well-controlled (HIV) on antiretroviral therapy (ART), if diagnosed with HIV
  • Has undetectable virus (HBV) viral load and has received HBV antiviral therapy, if hepatitis B surface antigen-positive
  • Has undetectable virus (HCV) viral load, if has a history of HCV infection

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has received sequential CRT for LS-SCLC (no overlap of radiotherapy with chemotherapy)
  • Has clinical or radiographic progression or deterioration while on concurrent CRT
  • Has pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
  • Has active or history of immune deficiency (with the exception of well-controlled on ART)
  • Has history of Kaposi's sarcoma and/or Multicentric Castleman's Disease, if diagnosed with HIV
  • Is expected to require any other form of antineoplastic therapy while on study
  • Has known additional that is progressing or required active treatment within the past 3 years
  • Has known central nervous system or
  • Has active disease that required systemic treatment in the past 2 years
  • Has active infection requiring systemic therapy (other than therapies permitted per protocol)
  • Has active or history of neurologic paraneoplastic syndrome
  • Has current pneumonitis/interstitial lung disease (ILD) or history of noninfectious pneumonitis/ILD that required
  • Has uncontrolled or significant cardiovascular disease
  • Has clinically severe pulmonary compromise from intercurrent pulmonary illnesses
  • Has history of intracranial or spinal cord bleeding
  • Has history of allogeneic tissue/solid organ transplant
  • Has not adequately recovered from major surgery or has ongoing surgical complications
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
564 participants (estimated)

Study arms

  • Experimental
    Gocatamig and durvalumab

    Participants will receive gocatamig and durvalumab until documented disease progression or discontinuation criteria are met.

    Biological: Gocatamig · Biological: Durvalumab · Drug: Rescue Medications

  • Active comparator
    Durvalumab

    Participants will receive durvalumab until documented disease progression or discontinuation criteria are met.

    Biological: Durvalumab

Interventions

  • BiologicalGocatamig

    Intravenous (IV) infusion

    Also known as: MK-6070, HPN328, DS-3280

  • BiologicalDurvalumab

    IV infusion

    Also known as: IMFINZI®

  • DrugRescue Medications

    Participants will receive rescue medications at the investigator's discretion. Recommended rescue medications include tocilizumab and/or siltuximab for treatment of cytokine release syndrome (CRS) and dexamethasone, acetaminophen, and diphenhydramine for CRS/infusion-related reaction prophylaxis.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or death due to any cause, whichever occurs first. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review will be reported.

    Time frame: Up to approximately 59 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause. OS for participants will be reported.

    Time frame: Up to approximately 87 months

  2. Distant Metastasis-Free Survival (DMFS)

    DMFS is defined as the time from randomization to the first documented distant metastasis or death due to any cause, whichever occurs first. Distant metastasis refers to cancer that has spread from the original (primary) tumor and beyond local tissues and lymph nodes to distant organs or distant lymph nodes. DMFS as assessed by investigator will be reported.

    Time frame: Up to approximately 87 months

  3. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 87 months

  4. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 87 months

  5. Mean Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 Item (EORTC QLQ-LC13) Cough (Items 31 and 32) Symptom Scale Score

    The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Participants respond to the question (Item 31) "Have you coughed?" and the question (Item 32) "Have you coughed up blood?" using a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower scale score indicates a better outcome. The mean change from baseline in cough (EORTC QLQ-LC13 Items 31 and 32) scale score will be reported.

    Time frame: Baseline and up to approximately 87 months

  6. Mean Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 40) Symptom Scale Score

    The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participants respond to the question (Item 40) "Have you had pain in your chest?" using a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower scale score indicates a better outcome. The mean change from baseline in chest pain (EORTC QLQ-LC13 Item 40) scale score will be reported.

    Time frame: Baseline and up to approximately 87 months

  7. Mean Change From Baseline in EORTC QLQ-LC13 Dyspnea (Items 33, 34, and 35) Symptom Scale Score

    The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participants respond to the question (Item 33) "Were you short of breath when you rested?", the question (Item 34) "Were you short of breath when you walked?", and the question (Item 35) "Were you short of breath when you climbed stairs?" using a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower scale score indicates a better outcome. The mean change from baseline in dyspnea (EORTC QLQ-LC13 Items 33, 34, and 35) scale score will be reported.

    Time frame: Baseline and up to approximately 87 months

  8. Time to Deterioration (TTD) in EORTC QLQ-LC13 Cough (Items 31 and 32) Symptom Scale Score

    EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participants respond to the question (Item 31) "Have you coughed?" and the question (Item 32) "Have you coughed up blood?" using a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw symptom scale scores are standardized, so that symptom scale scores range from 0-100. A lower symptom scale score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point deterioration (increase) in cough (Items 31 and 32), with confirmation at the subsequent visit of ≥10-point deterioration from baseline. A longer TTD indicates a better outcome. TTD in the symptom scale score for EORTC QLQ-LC13 (Items 31 and 32) will be reported.

    Time frame: Baseline and up to approximately 87 months

  9. TTD in EORTC QLQ-LC13 Chest Pain (Item 40) Symptom Scale Score

    EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participants respond to the question (Item 40) "Have you had pain in your chest?" using a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw symptom scale scores are standardized, so that symptom scale scores range from 0-100. A lower symptom scale score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point deterioration (increase) in chest pain (Item 40), with confirmation at the subsequent visit of ≥10-point deterioration from baseline. A longer TTD indicates a better outcome. TTD in the symptom scale score for EORTC QLQ-LC13 (Item 40) will be reported.

    Time frame: Baseline and up to approximately 87 months

  10. TTD in EORTC QLQ-LC13 Dyspnea (Items 33, 34, and 35) Symptom Scale Score

    EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participants respond to the question (Item 33) "Were you short of breath when you rested?", the question (Item 34) "Were you short of breath when you walked?", and the question (Item 35) "Were you short of breath when you climbed stairs?" using a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw symptom scale scores are standardized, so that symptom scale scores range from 0-100. A lower symptom scale score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point deterioration (increase) in dyspnea (Items 33, 34, and 35), with confirmation at the subsequent visit of ≥10-point deterioration from baseline. A longer TTD indicates a better outcome. TTD in the symptom scale score for EORTC QLQ-LC13 (Items 33, 34, and 35) will be reported.

    Time frame: Baseline and up to approximately 87 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2031, 60 months later.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 60 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2026
First posted
Nov 2, 2026
StartEst.
Dec 7, 2026
Primary completionEst.
Dec 8, 2031
CompletionEst.
Mar 10, 2036
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07908537
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Nov 2, 2026
Start date
Dec 7, 2026 (estimated)
Primary completion
Dec 8, 2031 (estimated)
Completion
Mar 10, 2036 (estimated)
Last update
Nov 2, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gocatamig

Start the discussion